Clinical Drug–Drug Pharmacokinetic Interaction Potential of Sucralfate with Other Drugs: Review and Perspectives
Autor: | Devaraj Venkatapura Chandrasekar, Muzeeb Syed, Suresh P. Sulochana, Ramesh Mullangi, Nuggehally R. Srinivas |
---|---|
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Drug Ketoprofen Naproxen Chemistry Pharmaceutical Sucralfate media_common.quotation_subject 030106 microbiology Biological Availability Pharmacy Pharmacology 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Pharmacokinetics Moxifloxacin medicine Animals Humans Drug Interactions Pharmacology (medical) media_common business.industry Bioavailability Pharmaceutical Preparations business medicine.drug |
Zdroj: | European Journal of Drug Metabolism and Pharmacokinetics. 41:469-503 |
ISSN: | 2107-0180 0378-7966 |
DOI: | 10.1007/s13318-016-0335-4 |
Popis: | Sucralfate, a complex of aluminium hydroxide with sulfated sucrose, forms a strong gastrointestinal tract (GIT) mucosal barrier with excellent anti-ulcer property. Because sucralfate does not undergo any significant oral absorption, sucralfate resides in the GIT for a considerable length of time. The unabsorbed sucralfate may alter the pharmacokinetics of the oral drugs by impeding its absorption and reducing the oral bioavailability. Because of the increased use of sucralfate, it was important to provide a reappraisal of the published clinical drug-drug interaction studies of sucralfate with scores of drugs. This review covers several category of drugs such as non-steroidal anti-inflammatory drugs, fluoroquinolones, histamine H2-receptor blockers, macrolides, anti-fungals, anti-diabetics, salicylic acid derivatives, steroidal anti-inflammatory drugs and provides pharmacokinetic data summary along with study design, objectives and key remarks. While the loss of oral bioavailability was significant for the fluoroquinolone class, it generally varied for other classes of drugs, suggesting that impact of the co-administration of sucralfate is manageable in clinical situations. Given the technology advancement in formulation development, it may be in order feasible to develop appropriate formulation strategies to either avoid or minimize the absorption-related issues when co-administered with sucralfate. It is recommended that consideration of both in vitro and preclinical studies may be in order to gauge the level of interaction of a drug with sucralfate. Such data may aid in the development of appropriate strategies to navigate the co-administration of sucralfate with other drugs in this age of polypharmacy. |
Databáze: | OpenAIRE |
Externí odkaz: |